ADAR1 Capital Management, LLC bought $1.6M of NextCure (NXTC)
Executed Jul 30, disclosed Aug 3, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 3), the stock returned +45.9% (delay-adjusted); from the execution session (Jul 30), +21.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
ADAR1 Capital Management, LLC (10% owner) filed 9 Form 4 reports as a reporting entity in the trailing twelve months (9 purchases, 0 sales), most often in Rallybio Corporation (RLYB). Across 6 priced purchase filings, the average 21-session return was +9.6% from execution and +15.9% from disclosure (delay-adjusted; derived). The largest single filing was $2.1M of RLYB (152,005 sh across 2 lots, as filed), executed May 4.
Healthcare · NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→